Sleuth vs. AlphaSense

The documents and the database, in one tool

AlphaSense says it “is not a life sciences database,” so pharma teams buy one alongside it. Sleuth searches the same biopharma documents and builds one table across every program from its own knowledge base.

For biopharma work, one tool instead of two

Sleuth has the documents you use AlphaSense for, analyst research included, and a knowledge base of drugs, trials, companies, and deals. It builds the table for your question from both.

Choose Sleuth for

Landscapes, partner and asset searches, and analyst research across every program, without a separate database or a week in Excel.

Keep AlphaSense if

Your team relies on its expert and KOL call transcripts, or researches industries outside life sciences.

Start at $249 a month instead of an annual contract per seat

An AlphaSense seat

Priced by its sales team

An annual contract, per seat. Which analyst reports you can open depends on your company’s account with each bank.

Sleuth

From $249 a month

Analyst research from 35+ providers comes with every plan, with no account needed at each bank.

See every plan

How Sleuth and AlphaSense compare

Sleuth

AlphaSense

What it is

Sleuth

Analysis built for your question, from a biopharma knowledge base and the documents behind it.

AlphaSense

A research platform for business and finance. In its own words, it “is not a life sciences database.”

Drugs, trials, companies, and deals

Sleuth

150K+ drugs, 1M+ trials from 20 registries, 400K+ companies, and 200K+ deals, connected in one knowledge base.

AlphaSense

Not included. Pharma teams buy a database such as Cortellis or Evaluate alongside it.

Tables across many sources

Sleuth

One row per program, built from every record and document about it, in the columns you need.

AlphaSense

Its table tool summarizes one document per row, so a program covered in 30 documents takes 30 rows.

Analyst research

Sleuth

Sell-side research from 35+ providers in every plan. Read any report in full, with no account needed at each bank.

AlphaSense

Broker research from many more banks. Which reports you can open depends on your company’s account with each bank.

Documents

Sleuth

Biopharma only: 5M+ corporate documents, 5M+ news articles and press releases, 300K+ patents, and conference abstracts.

AlphaSense

“A purpose-built financial research platform.” Most of its library covers other industries.

Sources

Sleuth

Click any value to see the filing, registry entry, or broker note behind it, with its date, a confidence score, and whether it’s sourced, inferred, or unknown. Sleuth flags the few cells worth checking.

AlphaSense

You check each answer yourself. It cites the passage it read, with no score for how much to trust the value.

Expert calls

Sleuth

Not included for now. Sleuth works from public documents, licensed data, and sell-side research.

AlphaSense

Expert and KOL call transcripts, and calls you set up yourself.

Price and access

Sleuth

From $249 a month, with published prices. Start today with a 14-day trial, no card.

AlphaSense

Annual contracts, per seat or for the enterprise, priced by its sales team.

A program’s documents and records, in one row

Sleuth puts a program’s phase and deals from the knowledge base next to what its filings, abstracts, and analyst notes say. Click any value to open the record or page it came from.

Example

One row per program, not per document

AlphaSense’s Generative Grid puts one document in each row and summarizes it. Sleuth builds one row per program from every record and document about it, in the columns you need.

“Which TROP2 ADCs are in Phase 3 or approved, and what were their latest deal and readout?”

Program

Owner

Phase

Latest deal

Latest readout

Datopotamab deruxtecan

Daiichi Sankyo

Approved

AstraZeneca, 2020, $1B upfrontCompany announcement

79% responded, first-line TNBCESMO 2025 abstract

Sacituzumab tirumotecan

Kelun-Biotech

Approved

Merck, 2022, $30M license feeCompany announcement

51% responded, cervical cancerSGO 2026 abstract

ESG401

Escugen (private)

Phase 3

Levena, 2021, terms undisclosedCompany announcement

82.9% responded, first-line TNBCESMO 2025 poster

FDA018

Fudan-Zhangjiang

Phase 3

None found

37.9% responded, pretreated TNBCASCO 2024 abstract

Columns Sleuth builds for you

Datopotamab deruxtecan

OwnerDaiichi Sankyo

PhaseApproved

Latest dealAstraZeneca, 2020, $1B upfrontCompany announcement

Latest readout79% responded, first-line TNBCESMO 2025 abstract

Sacituzumab tirumotecan

OwnerKelun-Biotech

PhaseApproved

Latest dealMerck, 2022, $30M license feeCompany announcement

Latest readout51% responded, cervical cancerSGO 2026 abstract

ESG401

OwnerEscugen (private)

PhasePhase 3

Latest dealLevena, 2021, terms undisclosedCompany announcement

Latest readout82.9% responded, first-line TNBCESMO 2025 poster

One row per program

Every program that fits, including private Chinese companies’ programs that no analyst covers.

A source on every value

Click a cell to see the abstract, filing, or deal record behind it.

Yours to keep

Saved to your Studio account, and exported to Excel, a deck, or an interactive analysis.

When to keep AlphaSense

Keep AlphaSense if your team relies on its expert and KOL call transcripts, or researches industries outside life sciences. For biopharma landscapes, partner searches, and analyst research, Sleuth covers the work.

Expert and KOL calls

Transcripts of expert and KOL interviews, and calls you set up yourself. Sleuth doesn’t offer these for now.

Industries outside life sciences

Research on companies and markets in technology, energy, consumer goods, and other sectors.

Company financials across sectors

Standardized financials and models for companies outside biopharma.

Questions about Sleuth and AlphaSense

Can Sleuth replace AlphaSense?

For biopharma work, yes: landscapes, partner and asset searches, and analyst research. Keep AlphaSense if your team relies on its expert and KOL call transcripts, or researches industries outside life sciences.

Doesn’t AlphaSense have a table tool too?

It does, and each row is one document you pick, summarized. AlphaSense’s help center says its results “are generated based on documents only — not companies directly.” In Sleuth, each row is a program, built from every record and document about it.

How much does Sleuth cost compared with AlphaSense?

Sleuth’s prices are published: Starter is $249 a month, and Team plans start at $499 a month for any number of people. Sell-side research comes with every plan, and you don’t need an account with each bank. AlphaSense sells annual contracts, per seat or for the enterprise, through its sales team.

Which analysts’ research is in Sleuth?

Sell-side research from 35+ providers: global and US healthcare banks, European brokers, independent research, and consulting firms, plus archives back to 2017 and China’s domestic brokers in English. Ask us for the full list.

Does Sleuth have expert-call transcripts?

Not for now. If expert and KOL calls are a big part of your research, keep AlphaSense or an expert network for them.

Can I use Sleuth in Claude?

Yes. Sleuth works in Claude, ChatGPT, and Copilot on every plan. A project you run from an AI tool draws on the same analyst research, and the reports open in that project in Studio.

Bring the question you’d search AlphaSense for

Set up in Claude, ChatGPT, or Copilot